Transdiagnostic Dimensional Profiling of Neurodevelopmental Disorders

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age3-11
SponsorIRCCS Eugenio Medea

About this trial

In recent years, the growing awareness of the multifactorial nature of neurodevelopmental disorders has stimulated interest in transdiagnostic approaches aimed at investigating underlying etiological mechanisms beyond traditional diagnostic categories. In this context, the present study seeks to provide a transdiagnostic profiling of both domain-general cognitive functions (attention, working memory, executive control) and domain-specific functions (phonological awareness, rapid naming, vocabulary, reading) underlying the main neurodevelopmental disorders in a large sample of preschool and school-age children (3-11 years), through the use of CRAB (Computerized Reading-related Assessment Battery). CRAB is a digital platform specifically developed by SUPSI and the Université de Genève to integrate, within a single testing environment, the assessment of the main domain-general and domain-specific cognitive functions underlying neurodevelopmental disorders. In particular, participating families will receive an email containing a link to access the CRAB platform, which will not include their personal data but rather a code provided by the staff of IRCCS Medea. A screen will open displaying several game-like tasks designed to measure both domain-general and domain-specific cognitive functions, which must be completed by the participating subject. The main objective is to obtain a fine-grained and multidimensional mapping of cognitive profiles prior to the standard diagnostic process, in order to identify early patterns of (a)typical or at-risk functioning.

Eligibility criteria

Qualifiers

Age between 3 and 11 years;

First access to the NPIA service at IRCCS Eugenio Medea (Bosisio Parini);

Suspected neurodevelopmental or psychopathological disorder;

Completion of the standard clinical diagnostic pathway;

Disqualifiers

Age outside the specified range;

Failure to complete the diagnostic pathway;

Lack of access to a compatible device (for remote administration);

Severe sensory impairments (uncorrected blindness or deafness);

Trial design

Treatments tested in this trial

  • Neuropsychological assessment

Treatment groups

300 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

IRCCS Eugenio Medea

Lead sponsor

Scuola Universitaria Professionale della Svizzera Italiana (SUPSI)

Collaborator

University of Geneva, Switzerland

Collaborator